Delving into the Latest Updates on Leonurine Sulfate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

NOX4

Action

modulators

Mechanism

NOX4 modulators(NADPH oxidase 4 modulators)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

HyperlipidemiasPrimary Hyperlipidemia

Inactive Indication-

Originator Organization

Zhuhai Hengqin New Area Zhongzhu Zhengtai Med Mgmt Co., Ltd.

Active Organization

Zhuhai Hengqin New Area Zhongzhu Zhengtai Med Mgmt Co., Ltd.

Fudan University

Inactive Organization-

License Organization

Fudan University

Zhuhai Hengqin New Area Zhongzhu Zhengtai Med Mgmt Co., Ltd.

Drug Highest PhasePhase 2

First Approval Date-

RegulationSpecial Review Project (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC14H21N3O5

InChIKeyWNGSUWLDMZFYNZ-UHFFFAOYSA-N

CAS Registry24697-74-3

View All Structures (2)

评估健康志愿者连续口服不同剂量硫酸益母草碱片的安全性、耐受性、药代动力学特性，为II期临床试验设计提供依据。评估健康志愿者连续口服不同剂量硫酸益母草碱片的药效动力学特性，探索硫酸益母草碱片对健康志愿者肠道菌群的影响，为II期临床试验及后期临床试验设计提供依据。

[Translation]

To evaluate the safety, tolerability and pharmacokinetic characteristics of different doses of Leonurine Sulfate Tablets in healthy volunteers, and provide a basis for the design of Phase II clinical trials. To evaluate the pharmacodynamic characteristics of different doses of Leonurine Sulfate Tablets in healthy volunteers, and explore the effect of Leonurine Sulfate Tablets on the intestinal flora of healthy volunteers, and provide a basis for the design of Phase II clinical trials and later clinical trials.

Start Date08 Aug 2019

Sponsor / Collaborator

Zhuhai Hengqin New Area Zhongzhu Zhengtai Med Mgmt Co., Ltd.

[+1]

CTR20190238

/ CompletedPhase 1

随机、两周期、两序列、交叉、单剂量、单一中心，评估食物对硫酸益母草碱片剂药代动力学特性影响试验

[Translation] A randomized, two-period, two-sequence, crossover, single-dose, single-center trial to evaluate the effect of food on the pharmacokinetic properties of leonurine sulfate tablets

评估食物对硫酸益母草碱片剂药代动力学特性的影响，为后续临床试验给药方案设计提供依据。

[Translation]

To evaluate the effect of food on the pharmacokinetic properties of leonurine sulfate tablets and provide a basis for the design of dosing regimens in subsequent clinical trials.

Start Date21 Feb 2019

Sponsor / Collaborator

Zhuhai Hengqin New Area Zhongzhu Zhengtai Med Mgmt Co., Ltd.

[+1]

100 Clinical Results associated with Leonurine Sulfate

Login to view more data

100 Translational Medicine associated with Leonurine Sulfate

Login to view more data

100 Patents (Medical) associated with Leonurine Sulfate

Login to view more data

327

Literatures (Medical) associated with Leonurine Sulfate

01 May 2025·European Journal of Medicinal Chemistry

Discovery of potential Leonurine-based therapeutic lead MJ210 attenuates Parkinson's disease pathogenesis via NF-κB and MAPK pathways: Mechanistic insights from in vitro and in vivo rotenone models

Article

Author: Garg, Shubham ; Khan, Juhee ; Gupta, Sanju ; Jash, Moumita ; Ghosh, Surajit ; Roy, Rajsekhar ; Arshi, Mohammad Umar ; Nayak, Prasunpriya

Parkinson's disease (PD) is a common neurodegenerative disease affecting motor and non-motor functions, with no effective treatment yet discovered. Neuroprotective compounds, both natural and synthetic, show promise but face challenges such as crossing the blood-brain barrier, limited serum stability, and higher toxicity. To tackle these obstacles, we have devised an innovative design strategy inspired by the neuroprotective properties of Leonurine, widely utilized in managing neurological disorders. Through rigorous screening of our compound library, we have identified a potent therapeutic molecule (MJ210) that exhibited remarkable efficacy in bolstering neuroprotection against rotenone-induced PD models, both in vitro and in vivo. Our findings revealed that administering MJ210 significantly increased neuronal survival in the SH-SY5Y model of PD. This was achieved by preventing apoptosis, reducing reactive oxygen species, mitigating mitochondrial dysfunction, and dampening neuroinflammation via ERK1/2-P38-JNK and P65-NFκB signaling pathways. In addition, MJ210 demonstrated remarkable neuroprotective abilities in vivo by significantly enhancing dopamine biosynthesis, alleviating motor dysfunction, improving balance and coordination, and reversing depression in rotenone-induced PD rats, even outperforming L-DOPA, the current gold standard treatment for PD. Therefore, MJ210 emerges as a significantly promising therapeutic candidate for PD, offering the potential for managing both the severity and progression of this disease.

01 Jan 2025·Free Radical Biology and Medicine

Leonurine restrains granulosa cell ferroptosis through SLC7A11/GPX4 axis to promote the treatment of polycystic ovary syndrome

Article

Author: Zhuan, Qingrui ; Xiong, Xianglei ; Zhou, Dan ; Liang, Chunxiao ; Fu, Xiangwei ; Xiong, xianglei ; Huang, Xiaohan ; Geng, Hucheng ; Du, Xingzhu ; Hou, Yunpeng ; Qi, Xinyu ; Liu, Zhiqiang ; Meng, Lin ; Zhang, Luyao

Polycystic ovary syndrome (PCOS) is a common endocrine disorder marked by ovarian dysfunction and metabolic abnormality. This study explores the therapeutic potential of leonurine (SCM-198) in PCOS. Our results show that SCM-198 treatment significantly improved ovarian function, hormone disorders and insulin resistance while reducing granulosa cell ferroptosis. This study provides the first evidence that SCM-198 modulates the gut microbiota composition, increases the abundance of Christensenella minuta, and boosts butyrate levels. Transcriptomic and metabolomic analyses revealed that PCOS patients exhibit granulosa cell ferroptosis and decreased butyrate levels in follicular fluid. Butyrate was shown to alleviate ferroptosis in granulosa cells via the SLC7A11/TXNRD1/GPX4 pathway, as confirmed in vitro with KGN cells. The therapeutic mechanism of SCM-198 in the management of PCOS via the gut microbiota-ovary axis involves the enhancement of gut microbiota and its metabolites. This intervention improves ovarian function and alleviates PCOS symptoms by targeting ferroptosis in granulosa cells.

01 Dec 2024·Biomaterials

Injectable bioadhesive hydrogel as a local nanomedicine depot for targeted regulation of inflammation and ferroptosis in rheumatoid arthritis

Article

Author: Xie, Chaoming ; Zhang, Kaibo ; Yang, Runze ; Fu, Weili ; Yan, Liwei ; Lu, Xiong ; Xu, Tianhao

Medicine intervention is the major clinical treatment used to relieve the symptoms and delay the progression of rheumatoid arthritis (RA), but is limited by its poor targeted delivery and short therapeutic duration. Herein, we developed an injectable and bioadhesive gelatin-based (Gel) hydrogel as a local depot of leonurine (Leon)-loaded and folate-functionalized polydopamine (FA-PDA@Leon) nanoparticles for anti-inflammation and chondroprotection in RA. The nanoparticles could protect Leon and facilitate its entry into the M1 phenotype macrophage for intracellular delivery of Leon, while the hydrogel tightly adhered to the tissues in the joint cavity and prolonged the retention of FA-PDA@Leon nanoparticles, thus achieving higher availability and therapeutic efficiency of Leon. In vitro and in vivo experiments demonstrated that the Gel/FA-PDA@Leon hydrogel could strongly suppress the inflammatory response by down-regulating the JAK2/STAT3 signaling pathway in macrophages and protect the chondrocytes from ferritinophagy/ferroptosis. This contributed to maintaining the structural integrity of articular cartilage and accelerating the joint functional recovery. This work provides an effective and convenient strategy to achieve higher bioavailability and long-lasting therapeutic duration of medicine intervention in arthritis diseases.

100 Deals associated with Leonurine Sulfate

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperlipidemias	Phase 2	China	Zhuhai Hengqin New Area Zhongzhu Zhengtai Med Mgmt Co., Ltd.	-
Hyperlipidemias	Phase 2	China	Fudan University	-
Primary Hyperlipidemia	Phase 1	China	Fudan University	06 May 2022
Primary Hyperlipidemia	Phase 1	China	Zhuhai Hengqin New Area Zhongzhu Zhengtai Med Mgmt Co., Ltd.	06 May 2022